Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Convertible Debt: 2019-2025

Historic Convertible Debt for Cytokinetics (CYTK) over the last 6 years, with Sep 2025 value amounting to $889.5 million.

  • Cytokinetics' Convertible Debt rose 61.30% to $889.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.5 million, marking a year-over-year increase of 61.30%. This contributed to the annual value of $552.4 million for FY2024, which is 0.62% up from last year.
  • Latest data reveals that Cytokinetics reported Convertible Debt of $889.5 million as of Q3 2025, which was up 60.57% from $554.0 million recorded in Q2 2025.
  • Cytokinetics' Convertible Debt's 5-year high stood at $889.5 million during Q3 2025, with a 5-year trough of $90.9 million in Q1 2021.
  • In the last 3 years, Cytokinetics' Convertible Debt had a median value of $550.6 million in 2024 and averaged $581.1 million.
  • Data for Cytokinetics' Convertible Debt shows a peak YoY soared of 480.48% (in 2022) over the last 5 years.
  • Cytokinetics' Convertible Debt (Quarterly) stood at $95.5 million in 2021, then skyrocketed by 471.70% to $545.8 million in 2022, then increased by 0.58% to $549.0 million in 2023, then rose by 0.62% to $552.4 million in 2024, then spiked by 61.30% to $889.5 million in 2025.
  • Its Convertible Debt was $889.5 million in Q3 2025, compared to $554.0 million in Q2 2025 and $553.1 million in Q1 2025.